Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 429 of 6351
-
AI could catch returning cancer months earlier than current tests
Diagnosis Not yet recruitingCurrent decision tools (TNM, MRI/PET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to dynamic perioperative data. SAFE-AI will build and v…
Sponsor: Università Politecnica delle Marche • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
New hope for kids with cashew allergy: daily drops may build tolerance
Disease control Not yet recruitingThe CASCADES study will investigate the safety and efficacy of sublingual immunotherapy (SLIT) for the treatment of cashew allergy in children ages 1-11 years old. Primary efficacy will be assessed after 18 months of cashew SLIT. Lab studies and an oral food challenge after 6 mon…
Phase 2 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can ketamine and talk therapy rewire the depressed brain?
Symptom relief Not yet recruitingThe goal of this clinical trial is to understand the effect of ketamine on the brain in people with treatment-resistant depression (TRD). TRD occurs in around a third of people with depression and leads to higher suicide rates compared to those with major depressive disorder. A d…
Phase 2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New shot could tame tough eczema Flare-Ups
Disease control Not yet recruitingStudy of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
Phase 3 • Sponsor: EHL Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Triple-Drug combo aims to stop AML relapse after remission
Disease control Not yet recruitingStudy Objectives: To evaluate the Relapse-Free Survival (RFS) and 1-year RFS rate in patients with Acute Myeloid Leukemia (AML) receiving maintenance therapy with Chidamide combined with Venetoclax and Azacitidine. Study Design: Prospective, Multicenter, Interventional Cohort …
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could stem cells save limbs? new trial tests healing power for leg ulcers
Disease control Not yet recruitingPeripheral arterial disease (PAD) can progress to critical limb ischemia (CLI) of the affected lower limb, characterized by pain at rest, ulcerations or gangrene, with a high risk of amputation. In this phase, the best treatment is arterial limb revascularization, but this is not…
Phase 1/2 • Sponsor: UPECLIN HC FM Botucatu Unesp • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for tough pancreatic cancer: targeted drug trial launches
Disease control Not yet recruitingThe purpose of this study is to determine the objective response rate (ORR) to lorigerlimab in patients with refractory pancreatic ductal adenocarcinoma (PDAC) and pathogenic germline variants (PGVs) in breast cancer type 1 or 2 susceptibility protein (BRCA1/2), Partner and Local…
Phase 2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New model may predict and prevent deadly transplant complication
Disease control Not yet recruitingThis study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Magic mushroom compound tested for depression in new brain scan study
Symptom relief Not yet recruitingDepression is the leading cause of disability worldwide, affecting an estimated 300 million people. Despite available treatments, response rates remain modest, and treatment resistance is common. Novel treatments are needed that act rapidly, produce lasting effects and work diffe…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Tailored therapy after stomach cancer surgery could boost survival
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate postoperative adaptive adjuvant therapy in patients with gastric or gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy plus immunotherapy and radical gastrectomy.The main questions it aims to answer are: 1. In p…
Phase 2/3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo targets tough lymphoma subtypes in early trial
Disease control Recruiting nowThis is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients …
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug INV-8989 targets Hard-to-Treat cancers with KRAS G12D mutation
Disease control Recruiting nowThis is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
Phase 1/2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Sound waves vs X-Rays: which guides heart stents better?
Disease control Not yet recruitingSTEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular i…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Two-Week chemo blast be just as good as three for AML?
Disease control Not yet recruitingObjective: This clinical trial aims to compare the efficacy and safety of the VA-CAG regimen administered as a two-week schedule versus a three-week schedule for induction remission in acute myeloid leukemia (AML). Key Research Questions: 1. Is the efficacy of the two-week VA-C…
Phase 2 • Sponsor: Hematology department of the 920th hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Precision radiotherapy targets rare breast tumors by genetic fingerprint
Disease control Not yet recruitingPhyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malign…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Supercharged immune cells take on Drug-Resistant infections
Disease control Stopped earlyEpstein Barr Virus (EBV) or Cytomegalovirus (CMV) infection results in significant morbidity and mortality in hematopoietic stem cell transplantation (HSCT) patients. HSCT patients often face opportunistic infections due to the immunosuppressive state during transplantation. Anti…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis is an open-label, dose-escalation and dose-expansion phase Ib/IIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of HCB101 in combination therapies in subjects with gastric or GEJ adenocarcinoma. A total of about 40 subjects will be enrolled in…
Phase 1/2 • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can shedding pounds after breast cancer keep it away?
Disease control CancelledThis is a feasibility study to gain an understanding of the willingness of women with a history of early stage breast cancer and current obesity to enroll in a weight-loss study, accept an assigned intervention (bariatric surgery with lifestyle intervention or lifestyle intervent…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Spirulina's secret protein may shield the liver during surgery
Disease control Recruiting nowThe goal of this study is to find out whether phycocyanin, a natural protein from spirulina, can help protect the liver and support recovery in adults having part of their liver removed. The study will also look at whether phycocyanin is safe to take.The main questions are: Does…
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
A week of dieting before liver surgery could cut bleeding and complications
Disease control Recruiting nowThe rationale for this study is to evaluate whether a standardized, preoperative, short-term Low Calorie Diet (LCD) reduces intraoperative bleeding and postoperative morbidity in liver surgery. Participants with a BMI of 30 or higher, scheduled for liver surgery, if accepting pa…
Sponsor: Region Skane • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC